Trial Profile
A Non-interventional, Multi-center, Retrospective Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia (ROSE Study)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Jan 2019
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil/rosuvastatin (Primary)
- Indications Dyslipidaemias; Essential hypertension
- Focus Therapeutic Use
- Acronyms ROSE Study
- Sponsors Daewoong Pharmaceutical
- 06 Jan 2017 New trial record